/PRNewswire/ Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine